# US 2015/0306077 A1 · Novel Compositions and Methods for Treating Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0306077 A1
- Document ID: US20150306077A1
- Status: Published application
- Kind: A1
- Application number: 14/698,718
- Filed: 2015-04-28
- Published: 2015-10-29
- Earliest claimed: 2011-10-28
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Bulent Ozpolat; Gabriel Lopez-Berestein; Kevin N. Dalby; Jiney Jose
- Web page: https://patentgrep.com/patent/US20150306077A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/404: Indoles, e.g. pindolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 209/18: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 471/14: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are methods and compositions inter alia for treating diseases, including hyperproliferative diseases, migraine headaches, and depression.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of treating cancer in a patient in need of such treatment, said method comprising administering a therapeutically effective amount of a compound having the formula:
wherein
R1A is independently hydrogen,
halogen, —CX1A3, —C(O)R7A, —C(O)—OR7A, —C(O)NR7AR8A, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2A is independently hydrogen,
halogen, —CX2A3, —C(O)R9A, —C(O)—OR9A, —C(O)NR9AR10A, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R1A and R2A are optionally joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
R3 is independently hydrogen, halogen, —CX33, —CN, —SO2Cl, —SO1R14, —SOkNR11R12, —NHNH2, —ONR11R12, —NHC═(O)NHNH2,
—NHC═(O)NR11R12, —N(O)m, —NR11R12, —C(O)R13, —C(O)—OR13, —O—C(O)—R13, —C(O)NR11R12, —NR11C(O)R13, —OR14, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R7A, R8A, R9A, R10A, R11, R12, R13, and R14 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
A1 is independently ═N— or ═CR3—;
k and m are independently 1 or 2;
n is independently an integer from 0 to 4;
z1 is independently an integer from 0 to 3; and
X1A, X2A, and X3 are independently —Cl, —Br, —I, or —F.

### Claim 22 (depends on 21)

The method of claim 21 having the formula:

### Claim 23 (depends on 21)

The method of claim 21 having the formula:

### Claim 24 (depends on 21)

The method of claim 21, wherein
R1A is independently hydrogen, unsubstituted alkyl, —C(O)R7A or —C(O)—OR7A; and
R7A is independently hydrogen, substituted or unsubstituted C1-C20 alkyl, substituted or unsubstituted 2 to 20 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocycloalkyl, substituted or unsubstituted C6-C10 aryl, or substituted or unsubstituted 5 to 10 membered heteroaryl.

### Claim 25 (depends on 21)

The method of claim 21, wherein
R2A is independently hydrogen, unsubstituted alkyl, —C(O)R9A or —C(O)—OR9A; and
R9A is independently hydrogen, substituted or unsubstituted C1-C20 alkyl, substituted or unsubstituted 2 to 20 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocycloalkyl, substituted or unsubstituted C6-C10 aryl, or substituted or unsubstituted 5 to 10 membered heteroaryl.

### Claim 26 (depends on 21)

The method of claim 21, wherein R3 is independently hydrogen, halogen, —C(O)R13, —O—C(O)—R13, —C(O)—OR13, —OR14, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 27 (depends on 21)

The method of claim 21, wherein
R3 is independently hydrogen or —OR14; and
R14 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

### Claim 28 (depends on 27)

The method of claim 27, wherein R14 is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.

### Claim 29 (depends on 27)

The method of claim 27, wherein R14 is independently substituted or unsubstituted alkyl.

### Claim 30 (depends on 27)

The method of claim 27, wherein R14 is independently substituted or unsubstituted C1-C20 alkyl.

### Claim 31 (depends on 27)

The method of claim 27, wherein R14 is independently substituted or unsubstituted C6-C16 alkyl.

### Claim 32 (depends on 27)

The method of claim 27, wherein R14 is independently unsubstituted C6-C16 alkyl.

### Claim 33 (depends on 21)

The method of claim 21, wherein A1 is ═CR3—.

### Claim 34 (depends on 21)

The method of claim 21, wherein A1 is ═N—.

### Claim 35 (depends on 21)

The method of claim 21, wherein A1 is ═CH—.

### Claim 36 (depends on 21)

The method of claim 21, wherein the compound is:

### Claim 37 (depends on 21)

The method of claim 21, wherein said cancer is breast cancer, ovarian cancer, pancreatic cancer, liver cancer, glioblastoma, glioma, lung cancer, prostate cancer, leukemia, or melanoma.

### Claim 38 (depends on 21)

The method of claim 21, wherein said cancer is breast cancer.

### Claim 39 (depends on 21)

The method of claim 21, wherein said cancer is metastatic cancer.

### Claim 40 (depends on 21)

The method of claim 21, wherein said compound is co-administered with a chemotherapeutic agent.
